UK Launches Bird Flu mRNA Vaccine Trial as Pandemic Preparedness Ramps Up
The UK's National Institute for Health and Care Research has launched a Phase 3 clinical trial for an investigational mRNA vaccine against bird flu, with approximately 4,000 adult volunteers across the UK and the United States set to participate in the landmark study.
The trial, sponsored by pharmaceutical company Moderna and supported by up to $54.3 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI), represents a significant step in global efforts to develop effective vaccines that could be deployed rapidly in the event of an H5N1 pandemic.
Background
The A(H5N1) strain of bird flu is currently circulating widely in wild birds, poultry, cattle, and other animals globally. While human-to-human transmission is not yet easy, it is considered a real possibility. Since 2024, there have been 116 confirmed human cases of H5 bird flu worldwide, predominantly linked to close contact with infected animals. The vaccine uses the same mRNA technology employed in the development of COVID-19 vaccines, recognised for its rapid production and adaptability to evolving strains.
Key Developments
The trial is particularly seeking to recruit individuals working in the poultry industry or those over 65, as these groups are considered most at risk. Clare Howard, a physiotherapist and chicken owner from Hampshire, was among the first UK volunteers to receive the vaccine in Southampton. The trial is being conducted despite the US Department of Health and Human Services cancelling hundreds of millions of dollars in previously committed funding for mRNA vaccine development, with CEPI stepping in to provide the necessary support.
If the vaccine proves successful, it could be manufactured at Moderna's plant in Harwell, Oxfordshire, which currently produces COVID-19 vaccines for the UK and has an annual production capacity of 100 million doses, expandable to 250 million during a pandemic. According to BBC News, Moderna has committed to allocating 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries.
Why It Matters
The trial represents a proactive approach to pandemic preparedness, drawing on lessons learned from the COVID-19 pandemic. The UK's involvement underscores its continued leadership in vaccine research and development, and the use of mRNA technology could significantly reduce the time needed to develop and deploy a vaccine in the event of a pandemic.
What's Next
The trial results are expected to inform regulatory decisions about the vaccine's licensure. If approved, the vaccine could be stockpiled as part of national pandemic preparedness plans, providing a critical line of defence against a potential H5N1 pandemic.
